References
1. Howells et al. Br J Dermatol. 2021;185:921–34.
2. Schneider-Burrus et al. Front Med (Lausanne). 2021;8:676241.
3. Garg et al. J Am Acad Dermatol. 2020;82:366–76.
4. Willems et al. Patient. 2022;15:207–18.
5. Ingram et al. Br J Dermatol. 2020;183:990–8.
6. Barmatz et al. Dermatology. 2022;238:772–84.
7. Nguyen et al. J Eur Acad Dermatol Venereol. 2021;35:50–61.
GB-DA-2400166 | March 2024
Can we let this continue?
Hidradenitis suppurativa (HS) is a burdensome, chronic, systemic, inflammatory skin disease that has a profound impact on patients’ quality of life.1-3 Between the 7.3 years on average to receive a diagnosis4-6 and limitations with current therapies, which can leave patients with HS a high level of unmet3, it’s time to stop HS falling through the cracks of our healthcare systems.7